New Phase 1 Trial Tests ACM-CpG Immunotherapy for Appendix and Colorectal Cancer Spread Within the Abdomen

A new investigational treatment is being studied for appendiceal and colorectal cancers that have spread within the abdomen. A Phase 1 clinical trial at Brown University Health is testing ACM-CpG, an experimental immunotherapy being developed by Arcamyra Therapeutics.

How ACM-CpG works

ACM-CpG is designed to be delivered directly into the abdominal cavity, where it may help stimulate the immune system to recognize and fight cancer cells. This first-in-human study will primarily evaluate the treatment’s safety, while also looking for early signs that it may be effective.

Who the ACM-CpG trial is for

The trial is studying patients with appendiceal or colorectal adenocarcinoma with peritoneal metastases (cancer that has spread to the lining of the abdomen) whose disease has not responded well to previous treatments.

NBC 10 News recently featured the trial and spoke with principal investigator Dr. Khaldoun Almahanna. Watch the NBC 10 feature.

Why early trials matter

While this treatment is still at a very early stage of development, trials like this are an important part of advancing new treatment options for people facing peritoneal disease.

Learn more

Trial ID: NCT07658196. View the trial on ClinicalTrials.gov.

Explore this trial and others in ACPMP’s Clinical Trials Database, and talk with your care team about whether a clinical trial may be right for you.

This summary is for general information only and is not medical advice. Please talk with your care team about what this research may mean for you.